0000000000366058

AUTHOR

Carlo Scolastico

showing 2 related works from this author

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases

2005

Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data. In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy. Both prevalent and incident cases were enrolled. A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC). In 567 patients (5.7%) the diagnosis was not established. Hepatitis C virus (HCV) was found in 69.9% of the patients and was the only etiological factor…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCarcinoma HepatocellularCirrhosisalcohol abuseHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeRisk FactorsVirologyPrevalencemedicineHBVHumansAgedbusiness.industryIncidenceLiver DiseasesLiver NeoplasmsHepatitis CMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis CVirologyAlcoholismInfectious DiseasesItalyHepatocellular carcinomaChronic DiseaseHCVFemaleViral hepatitisbusiness
researchProduct

Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study*.

2005

Summary.  We carried out a multicentre study on 2830 patients with chronic liver disease from 79 liver units (25 in northern, 24 in central and 30 in southern Italy) to evaluate naturally acquired immunity against hepatitis A virus (HAV) in relation to age, sex, geographical area of origin and entity of liver disease, and to define the strategy for specific vaccination. Antibody to HAV (anti-HAV) was detected in 1514 (53.5%) of the 2830 patients tested; the prevalence was 50.4% in males and 59.1% in females. Both in central and southern Italy the prevalence of anti-HAV positive subjects increased with increasing age from 43.3 and 44.7%, respectively, in the 0–30-year-old subjects to 80.1 an…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentHepatitis A AntibodiesChronic liver diseaseLiver diseaseSeroepidemiologic StudiesVirologyInternal medicinePrevalencemedicineHumansIn patientChildChronic liver disease HAV infection HAV vaccination HBV chronic infection HCV chronic infection Total anti-HAVAgedAged 80 and overHigh prevalenceHepatologybiologybusiness.industryLiver DiseasesInfantHepatitis AHepatitis AMiddle Agedmedicine.diseaseVaccinationCross-Sectional StudiesInfectious DiseasesItalyChild PreschoolImmunoglobulin GChronic DiseaseImmunologybiology.proteinFemaleAntibodybusinessHepatitis A Virus Human
researchProduct